Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
private:k-paxpharmaceuticals | 1341054 | Nov 7th, 2017 12:00AM | K-PAX Pharmaceuticals | 84 | 5.00 | Open | Pharmaceuticals | Nov 7th, 2017 04:57PM | Nov 7th, 2017 04:57PM | K-PAX Pharmaceuticals is a privately held biotech company currently developing proprietary compounds to treat fatigue, decreased alertness and decreased cognition in Parkinson's disease, Alzheimer’s disease, and cancer-related fatigue. Our patented compound - KPAX002 - is a proprietary modified version of methylphenidate. It is an enhanced, safer CNS stimulant, bolstered by our proprietary mitochondrial technology, with the ability to safely alleviate fatigue and decreased alertness in patients with neurodegenerative and other serious diseases. We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy at alleviating severe fatigue and decreased alertness symptoms in chronically ill patients. This indication represents a serious unmet medical need with a large population. The FDA is highly supportive of identifying a fatigue treatment in multiple disease states. We are concurrently pursuing several regulatory indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease decreased alertness 3) Cancer-related fatigue 4) Myalgic encephalomyelitis | K-PAX Pharmaceuticals | Health Care | Health Care Equipment & Services | |||||||||
private:k-paxpharmaceuticals | 1341054 | Nov 1st, 2017 12:00AM | K-PAX Pharmaceuticals | 83 | 5.00 | Open | Pharmaceuticals | Nov 1st, 2017 04:43AM | Nov 1st, 2017 04:43AM | K-PAX Pharmaceuticals is a privately held biotech company currently developing proprietary compounds to treat fatigue, decreased alertness and decreased cognition in Parkinson's disease, Alzheimer’s disease, and cancer-related fatigue. Our patented compound - KPAX002 - is a proprietary modified version of methylphenidate. It is an enhanced, safer CNS stimulant, bolstered by our proprietary mitochondrial technology, with the ability to safely alleviate fatigue and decreased alertness in patients with neurodegenerative and other serious diseases. We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy at alleviating severe fatigue and decreased alertness symptoms in chronically ill patients. This indication represents a serious unmet medical need with a large population. The FDA is highly supportive of identifying a fatigue treatment in multiple disease states. We are concurrently pursuing several regulatory indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease decreased alertness 3) Cancer-related fatigue 4) Myalgic encephalomyelitis | K-PAX Pharmaceuticals | Health Care | Health Care Equipment & Services |